skip to content
Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies Preview this item
ClosePreview this item
Checking...

Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies

Author: Philippe Gorry; Diego Useche; National Bureau of Economic Research,
Publisher: Cambridge, Mass. : National Bureau of Economic Research, 2017.
Series: Working paper series (National Bureau of Economic Research), no. 24021.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage drug innovation in order to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceutical and biotechnology start-up companies may be considered as relevant signals in attracting entrepreneurial finance and increasing the amount  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Patents
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Philippe Gorry; Diego Useche; National Bureau of Economic Research,
OCLC Number: 1012490115
Notes: "November 2017."
Description: 1 online resource (28 pages) : illustrations
Series Title: Working paper series (National Bureau of Economic Research), no. 24021.
Other Titles: Gorry-Useche NBER PPMf2017
Responsibility: Philippe Gorry, Diego Useche.

Abstract:

Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage drug innovation in order to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceutical and biotechnology start-up companies may be considered as relevant signals in attracting entrepreneurial finance and increasing the amount invested at the time of the Initial Public Offering (IPO) in the US stock markets. We found that the signaling power of ODD is positively and statistically significant for IPO investors in stock markets. Regression results also suggest that ODDs are stronger than patent applications in attracting IPO investors. Scholarly and policy implications are discussed in the light of the signaling theory and drug development policies.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1012490115> # Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "1012490115" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mau> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Place/united_states> ; # United States.
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_law_and_legislation_united_states> ; # Orphan drugs--Law and legislation--United States
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/drugs> ; # Drugs
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_economic_aspects_united_states> ; # Orphan drugs--Economic aspects--United States
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_law_and_legislation> ; # Orphan drugs--Law and legislation
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/drug_development_economic_aspects_united_states> ; # Drug development--Economic aspects--United States
    schema:about <http://experiment.worldcat.org/entity/work/data/4629061759#Topic/drugs_united_states_patents> ; # Drugs--United States--Patents
    schema:alternateName "Gorry-Useche NBER PPMf2017" ;
    schema:author <http://experiment.worldcat.org/entity/work/data/4629061759#Person/gorry_philippe> ; # Philippe Gorry
    schema:author <http://experiment.worldcat.org/entity/work/data/4629061759#Person/useche_diego> ; # Diego Useche
    schema:bookFormat schema:EBook ;
    schema:datePublished "2017" ;
    schema:description "Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage drug innovation in order to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceutical and biotechnology start-up companies may be considered as relevant signals in attracting entrepreneurial finance and increasing the amount invested at the time of the Initial Public Offering (IPO) in the US stock markets. We found that the signaling power of ODD is positively and statistically significant for IPO investors in stock markets. Regression results also suggest that ODDs are stronger than patent applications in attracting IPO investors. Scholarly and policy implications are discussed in the light of the signaling theory and drug development policies."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/4629061759> ;
    schema:genre "Patents"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4629061759#Series/working_paper_series_national_bureau_of_economic_research> ; # Working paper series (National Bureau of Economic Research) ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4629061759#Series/nber_working_paper_series> ; # NBER working paper series ;
    schema:name "Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies"@en ;
    schema:productID "1012490115" ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/4629061759#Organization/national_bureau_of_economic_research> ; # National Bureau of Economic Research,
    schema:url <https://doi.org/10.3386/w24021> ;
    schema:url <http://papers.nber.org/papers/w24021> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1012490115> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/4629061759#Organization/national_bureau_of_economic_research> # National Bureau of Economic Research,
    a schema:Organization ;
    schema:name "National Bureau of Economic Research," ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Person/gorry_philippe> # Philippe Gorry
    a schema:Person ;
    schema:familyName "Gorry" ;
    schema:givenName "Philippe" ;
    schema:name "Philippe Gorry" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Person/useche_diego> # Diego Useche
    a schema:Person ;
    schema:familyName "Useche" ;
    schema:givenName "Diego" ;
    schema:name "Diego Useche" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Place/united_states> # United States.
    a schema:Place ;
    schema:name "United States." ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Series/nber_working_paper_series> # NBER working paper series ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1012490115> ; # Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies
    schema:name "NBER working paper series ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Series/working_paper_series_national_bureau_of_economic_research> # Working paper series (National Bureau of Economic Research) ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1012490115> ; # Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies
    schema:name "Working paper series (National Bureau of Economic Research) ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Topic/drug_development_economic_aspects_united_states> # Drug development--Economic aspects--United States
    a schema:Intangible ;
    schema:name "Drug development--Economic aspects--United States"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Topic/drugs_united_states_patents> # Drugs--United States--Patents
    a schema:Intangible ;
    schema:name "Drugs--United States--Patents"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_economic_aspects_united_states> # Orphan drugs--Economic aspects--United States
    a schema:Intangible ;
    schema:name "Orphan drugs--Economic aspects--United States"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_law_and_legislation> # Orphan drugs--Law and legislation
    a schema:Intangible ;
    schema:name "Orphan drugs--Law and legislation"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629061759#Topic/orphan_drugs_law_and_legislation_united_states> # Orphan drugs--Law and legislation--United States
    a schema:Intangible ;
    schema:name "Orphan drugs--Law and legislation--United States"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1012490115>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1012490115> ; # Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies
    schema:dateModified "2019-06-28" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.